Added value of electrical impedance spectroscopy in adjunction of colposcopy: a prospective cohort study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
29 10 2023
Historique:
medline: 31 10 2023
pubmed: 30 10 2023
entrez: 29 10 2023
Statut: epublish

Résumé

To assess whether electrical impedance spectroscopy (EIS) as an adjunctive technology enhances the performance of colposcopy. Prospective cohort study. University Hospital colposcopy clinic. Colposcopy with EIS for 647 women and conventional colposcopy for 962 women. Comparison of the performance of colposcopy by referral cervical cytology in two cohorts, with and without EIS as an adjunctive technology. Prevalence of cervical intraepithelial neoplasia grade 2 or worse (CIN2+), diagnostic testing accuracy to detect CIN2+ with and without EIS and their relative differences between cohorts. The prevalence of CIN2+ varied between the cohorts according to referral cytology: 17.0% after abnormal squamous cells of unknown significance referral cytology in EIS cohort and 9.1% in the reference cohort, 16.5% and 18.9% after low-grade squamous intraepithelial lesion (LSIL), 44.3% and 58.2% after atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (HSIL) (atypical squamous cells that cannot exclude HSIL), and 81.9% and 77.0% after HSIL cytology, respectively. Sensitivity to detect CIN2+ was higher in the EIS cohort, varying from 1.79 (95% CI 1.30 to 2.45) after LSIL referral cytology to 1.16 (95% CI 1.09 to 1.23) after HSIL referral cytology, with correspondingly lower specificity after any referral cytology. Colposcopy with EIS had overall higher sensitivity but lower specificity to detect CIN2+ than conventional colposcopy. CIN2+ prevalence rates were, however, not consistently higher in the EIS cohort, suggesting innate differences between the cohorts or truly lower detection rates of CIN2+ for EIS, highlighting the need for randomised controlled trials on the effectiveness of EIS.

Identifiants

pubmed: 37899156
pii: bmjopen-2023-074921
doi: 10.1136/bmjopen-2023-074921
pmc: PMC10619076
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e074921

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

J Clin Oncol. 2015 Jan 1;33(1):83-9
pubmed: 25422481
J Obstet Gynaecol Res. 2023 Apr;49(4):1222-1229
pubmed: 36658620
Eur J Obstet Gynecol Reprod Biol. 2022 Aug;275:41-45
pubmed: 35724563
Acta Obstet Gynecol Scand. 2020 Aug;99(8):1064-1070
pubmed: 32105344
Eur J Obstet Gynecol Reprod Biol. 2017 Apr;211:194-198
pubmed: 28292693
BJOG. 2013 Mar;120(4):400-10; discussion 410-1
pubmed: 23289897
BJOG. 2020 Sep;127(10):1260-1267
pubmed: 32279427
BJOG. 2014 Aug;121(9):1117-26
pubmed: 24494663
J Low Genit Tract Dis. 2017 Oct;21(4):261-267
pubmed: 28953116
Lancet. 2000 Mar 11;355(9207):892-5
pubmed: 10752706
Eur J Obstet Gynecol Reprod Biol. 2019 Sep;240:182-186
pubmed: 31302386
J Gynecol Obstet Hum Reprod. 2017 Nov;46(9):669-673
pubmed: 28866125
Int J Cancer. 2023 Mar 15;152(6):1060-1068
pubmed: 36093582
BMJ. 2019 Feb 6;364:l240
pubmed: 30728133
J Electr Bioimpedance. 2020 Nov 06;11(1):81-86
pubmed: 33584907
BJOG. 2012 Oct;119(11):1293-301
pubmed: 22882742
Gynecol Oncol. 2019 Aug;154(2):354-359
pubmed: 31176553
Ginekol Pol. 2019;90(11):628-632
pubmed: 31802462
Cancer. 2006 Oct 25;108(5):298-305
pubmed: 16544318
J Low Genit Tract Dis. 2016 Jul;20(3):234-8
pubmed: 27243143
J Low Genit Tract Dis. 2011 Jul;15(3):180-8
pubmed: 21436729
Am J Obstet Gynecol. 2010 Oct;203(4):321.e1-6
pubmed: 20633870
Gynecol Oncol. 2009 Nov;115(2):267-71
pubmed: 19744703
J Low Genit Tract Dis. 2012 Oct;16(4):421-6
pubmed: 22669079
Obstet Gynecol. 2008 Jan;111(1):7-14
pubmed: 18165387
BJOG. 2017 Aug;124(9):1394-1401
pubmed: 28102931

Auteurs

Laura Bergqvist (L)

Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland laura.bergqvist@hus.fi.

Annu Heinonen (A)

Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Xavier Carcopino (X)

Department of Obstetrics and Gynaecology, APHM, AMU, Marseille, France.

Charles Redman (C)

Department of Obstetrics and Gynaecology, University Hospital of North Midlands, Stoke-on-Trent, UK.

Karoliina Aro (K)

Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Mari Kiviharju (M)

Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Seppo Virtanen (S)

Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Pirjo-Liisa Omar (PL)

Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Laura Kotaniemi-Talonen (L)

Department of Obstetrics and Gynaecology, Tampere University Hospital, Tampere, Finland.
Department of Obstetrics and Gynaecology, Faculty of Medecine and Health Technology, Tampere University, Tampere, Finland.

Karolina Louvanto (K)

Department of Obstetrics and Gynaecology, Tampere University Hospital, Tampere, Finland.
Department of Obstetrics and Gynaecology, Faculty of Medecine and Health Technology, Tampere University, Tampere, Finland.

Pekka Nieminen (P)

Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Ilkka Kalliala (I)

Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Department of Metabolism, Digestion and Reproduction and Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Faculty of Medecine, Imperial College, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH